BC Week In Review | Aug 17, 2018
Clinical News

RXi's subretinal fibrosis therapy well tolerated in Phase I/II

RXi Pharmaceuticals Corp. (NASDAQ:RXII) said RXI-109 was well tolerated with no treatment-related adverse events or dose-limiting toxicities (DLTs) reported in the Phase I/II RXI-109-1501 trial in nine patients with advanced neovascular age-related macular degeneration (AMD)...
BC Week In Review | Jun 8, 2018
Company News

RXi, Iovance Biotherapeutics combining technologies to treat solid tumors

RXi Pharmaceuticals Corp. (NASDAQ:RXII) and Iovance Biotherapeutics (NASDAQ:IOVA) will evaluate combining RXi's self-delivering RNAi technology with Iovance's Tumor Infiltrating Lymphocytes (TILs) in the treatment of solid tumors. The partners said the combination will be "explored...
BC Extra | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

Orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said Deputy CEO and CFO Gil Efron will leave at the end of the year. Chaime Orlev will become CFO, effective Jan. 1, 2018. Orlev was CFO...
BC Week In Review | Jul 5, 2017
Clinical News

RXi completes enrollment in Phase I/II of RXI-109 for retinal scarring

RXi Pharmaceuticals Corp. (NASDAQ:RXII) completed enrollment of about 9 patients with advanced wet age-related macular degeneration (AMD) in the Phase I/II Study RXI-109-1501 evaluating once-monthly intravitreal RXI-109 for 4 months to reduce the progression of...
BC Week In Review | May 26, 2017
Company News

PCI, RXi extend preclinical collaboration

PCI Biotech Holding ASA (OSE:PCIB) and RXi Pharmaceuticals Corp. (NASDAQ:RXII) extended a 2015 preclinical research collaboration and will conduct new studies to assess the compatibility of the companies’ immuno-oncology technologies. The partners said they will...
BioCentury | Jan 6, 2017
Finance

Good riddance

  Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead. The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration....
BC Week In Review | Dec 21, 2016
Financial News

RXi completes follow-on

RXi raised $10 million through the sale of 2.1 million class A units at $0.90 and 8,082 class B units at $1,000 in a follow-on underwritten by Ladenburg Thalmann and Griffin Securities. Each class A...
BC Week In Review | Nov 15, 2016
Financial News

RXi amends follow-on

RXi amended its follow-on and now plans to sell 2 million class A units and 9,600 class B units. The company also added Griffin Securities as an underwriter; Ladenburg Thalmann is also an underwriter. The...
BC Week In Review | Oct 31, 2016
Financial News

RXi Pharmaceuticals proposes follow-on

RXi Pharmaceuticals Corp. (NASDAQ:RXII), Westborough, Mass.  Business: Gene/Cell therapy, Dermatology, Ophthalmic  Date announced: 2016-10-21  Type: Follow-on  To be raised: Up to $20.7 million  Units: TBD  Price Prior: $1.19  Underwriter: Ladenburg Thalmann  Note: Each class A...
BC Week In Review | Oct 17, 2016
Company News

MirImmune, RXi Pharmaceuticals deal

RXi received an exclusive option to acquire immunotherapy company MirImmune. If exercised, MirImmune would receive a 19.99% stake in RXi and would be eligible for undisclosed milestones. The stake is valued at about $2.2 million...
Items per page:
1 - 10 of 114
BC Week In Review | Aug 17, 2018
Clinical News

RXi's subretinal fibrosis therapy well tolerated in Phase I/II

RXi Pharmaceuticals Corp. (NASDAQ:RXII) said RXI-109 was well tolerated with no treatment-related adverse events or dose-limiting toxicities (DLTs) reported in the Phase I/II RXI-109-1501 trial in nine patients with advanced neovascular age-related macular degeneration (AMD)...
BC Week In Review | Jun 8, 2018
Company News

RXi, Iovance Biotherapeutics combining technologies to treat solid tumors

RXi Pharmaceuticals Corp. (NASDAQ:RXII) and Iovance Biotherapeutics (NASDAQ:IOVA) will evaluate combining RXi's self-delivering RNAi technology with Iovance's Tumor Infiltrating Lymphocytes (TILs) in the treatment of solid tumors. The partners said the combination will be "explored...
BC Extra | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

Orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said Deputy CEO and CFO Gil Efron will leave at the end of the year. Chaime Orlev will become CFO, effective Jan. 1, 2018. Orlev was CFO...
BC Week In Review | Jul 5, 2017
Clinical News

RXi completes enrollment in Phase I/II of RXI-109 for retinal scarring

RXi Pharmaceuticals Corp. (NASDAQ:RXII) completed enrollment of about 9 patients with advanced wet age-related macular degeneration (AMD) in the Phase I/II Study RXI-109-1501 evaluating once-monthly intravitreal RXI-109 for 4 months to reduce the progression of...
BC Week In Review | May 26, 2017
Company News

PCI, RXi extend preclinical collaboration

PCI Biotech Holding ASA (OSE:PCIB) and RXi Pharmaceuticals Corp. (NASDAQ:RXII) extended a 2015 preclinical research collaboration and will conduct new studies to assess the compatibility of the companies’ immuno-oncology technologies. The partners said they will...
BioCentury | Jan 6, 2017
Finance

Good riddance

  Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead. The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration....
BC Week In Review | Dec 21, 2016
Financial News

RXi completes follow-on

RXi raised $10 million through the sale of 2.1 million class A units at $0.90 and 8,082 class B units at $1,000 in a follow-on underwritten by Ladenburg Thalmann and Griffin Securities. Each class A...
BC Week In Review | Nov 15, 2016
Financial News

RXi amends follow-on

RXi amended its follow-on and now plans to sell 2 million class A units and 9,600 class B units. The company also added Griffin Securities as an underwriter; Ladenburg Thalmann is also an underwriter. The...
BC Week In Review | Oct 31, 2016
Financial News

RXi Pharmaceuticals proposes follow-on

RXi Pharmaceuticals Corp. (NASDAQ:RXII), Westborough, Mass.  Business: Gene/Cell therapy, Dermatology, Ophthalmic  Date announced: 2016-10-21  Type: Follow-on  To be raised: Up to $20.7 million  Units: TBD  Price Prior: $1.19  Underwriter: Ladenburg Thalmann  Note: Each class A...
BC Week In Review | Oct 17, 2016
Company News

MirImmune, RXi Pharmaceuticals deal

RXi received an exclusive option to acquire immunotherapy company MirImmune. If exercised, MirImmune would receive a 19.99% stake in RXi and would be eligible for undisclosed milestones. The stake is valued at about $2.2 million...
Items per page:
1 - 10 of 114